New Spina Bifida Treatment Transforms Lives in Trial

When Michelle Johnson's son Tobi was born in 2022, she called his abilities "nothing short of a miracle." That miracle came from a pioneering treatment that could change everything for babies diagnosed with spina bifida.

Scientists at the University of California, Davis have developed a procedure that repairs babies' spines in the womb using stem cells from their mothers' placentas. The technique combines traditional surgical repair with regenerative medicine, giving developing babies a better shot at normal movement and quality of life.

Spina bifida happens when a baby's spinal cord doesn't form properly during pregnancy. The condition affects about 166,000 babies born worldwide each year and can lead to lifelong disabilities including paralysis, mobility challenges, and other health complications.

The new treatment showed remarkable promise in its first human trial. All six mothers who participated saw positive outcomes for their children, with results published this week in the prestigious Lancet health journal.

The Ripple Effect

Diana Farmer, who chairs UC Davis's Department of Surgery and led the research, says the procedure "paves the way for new treatment options for children with birth defects." The implications stretch far beyond spina bifida itself.

Co-inventor Aijun Wang called it "a major step toward a new kind of fetal therapy," suggesting the stem cell approach could eventually help treat other conditions before birth. UK charity Shine, which supports families affected by spina bifida, described the results as "very exciting."

While researchers caution that more studies are needed before the treatment becomes widely available, the phase one trial proves the concept works safely in humans. That's the hardest hurdle cleared.

For families like the Johnsons, the wait for broader availability will be worth it if other children can experience what Tobi has: a chance at the active, independent life every parent hopes for their child.